Reducing Cardiovascular Risk: A Longevity Protocol

Cardiovascular disease develops over decades, driven primarily by the accumulation of cholesterol-laden plaque within arterial walls — a process called atherosclerosis. The critical insight from modern preventive cardiology is that LDL-C and ApoB-containing lipoproteins are the central causal agents, not merely risk markers. Decades of cumulative LDL exposure, sometimes called "LDL-years," better predicts event risk than any single measurement.

The foundation of cardiovascular risk reduction is lifestyle: aerobic exercise reduces resting heart rate, improves endothelial function, raises HDL, and lowers triglycerides. Zone 2 training at 60–70% of maximum heart rate for 150–180 minutes weekly is the current evidence-backed minimum. Mediterranean diet adherence has shown a 30% reduction in major cardiovascular events in the PREDIMED trial, driven by anti-inflammatory polyphenols, monounsaturated fatty acids, and omega-3 content.

Advanced diagnostics have transformed our ability to identify subclinical disease. Coronary artery calcium (CAC) scoring provides an absolute measure of existing plaque burden and stratifies patients who benefit most from statin therapy. A CAC score of zero in individuals over 50 with borderline risk profiles may allow safe deferral of statins; a score above 100 generally warrants aggressive LDL lowering to below 70 mg/dL. ApoB measurement is more predictive than LDL-C alone and should guide target thresholds.

Pharmacological intervention with statins remains one of the best-studied longevity interventions in existence, with consistent 25–35% relative risk reduction for major cardiovascular events across primary and secondary prevention trials. For those who cannot tolerate statins, bempedoic acid and PCSK9 inhibitors offer alternatives. Low-dose aspirin in primary prevention has a more nuanced risk-benefit profile in the modern era and should not be assumed appropriate without individual assessment.